GERN — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

10.4

Margin Of Safety %

Put/Call OI Ratio

0.46

EPS Next Q Diff

0.02

EPS Last/This Y

0.11

EPS This/Next Y

0.1

Price

1.75

Target Price

3.4

Analyst Recom

Performance Q

31.82

Upside

-361.5%

Beta

0.73

Ticker: GERN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	GERN	1.63	0.56	0.32	70165
2026-03-10	GERN	1.64	0.56	0.02	70282
2026-03-11	GERN	1.665	0.56	0.04	70165
2026-03-12	GERN	1.61	0.56	1.51	70753
2026-03-13	GERN	1.6	0.56	1.98	70753
2026-03-17	GERN	1.625	0.56	0.34	70971
2026-03-18	GERN	1.545	0.57	0.12	71074
2026-03-19	GERN	1.545	0.57	0.99	71125
2026-03-20	GERN	1.455	0.57	0.12	71326
2026-03-23	GERN	1.545	0.50	0.01	50063
2026-03-24	GERN	1.51	0.47	0.04	52502
2026-03-25	GERN	1.575	0.47	0.08	52583
2026-03-26	GERN	1.535	0.46	1.07	52701
2026-03-27	GERN	1.405	0.46	0.00	52748
2026-03-30	GERN	1.415	0.46	0.01	53161
2026-03-31	GERN	1.485	0.46	0.67	53193
2026-04-01	GERN	1.655	0.47	0.04	53786
2026-04-02	GERN	1.665	0.46	0.16	54602
2026-04-06	GERN	1.755	0.45	0.05	54673
2026-04-07	GERN	1.745	0.46	0.00	54487
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	GERN	1.63	33.3	47.7	-0.02
2026-03-10	GERN	1.64	33.3	47.9	-0.02
2026-03-11	GERN	1.66	33.3	47.9	-0.02
2026-03-12	GERN	1.61	33.3	48.1	-0.02
2026-03-13	GERN	1.59	33.3	48.0	-0.02
2026-03-17	GERN	1.62	33.3	48.0	-0.02
2026-03-18	GERN	1.55	33.3	48.1	-0.02
2026-03-19	GERN	1.54	33.3	48.0	-0.02
2026-03-20	GERN	1.46	33.3	48.2	-0.02
2026-03-23	GERN	1.54	33.3	47.7	-0.02
2026-03-24	GERN	1.51	33.3	48.0	-0.02
2026-03-25	GERN	1.58	33.3	47.8	-0.02
2026-03-26	GERN	1.54	33.3	48.0	-0.02
2026-03-27	GERN	1.40	33.3	48.3	-0.02
2026-03-30	GERN	1.41	33.3	47.9	-0.02
2026-03-31	GERN	1.49	33.3	47.7	-0.02
2026-04-01	GERN	1.65	33.3	47.5	-0.02
2026-04-02	GERN	1.66	33.3	47.9	-0.02
2026-04-06	GERN	1.75	33.3	47.7	-0.02
2026-04-07	GERN	1.75	33.3	48.0	-0.02
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	GERN	-0.03	-4.18	10.70
2026-03-10	GERN	-0.03	-4.18	10.70
2026-03-11	GERN	-0.03	-4.18	9.97
2026-03-12	GERN	-0.03	-4.18	9.97
2026-03-13	GERN	-0.03	-4.18	9.97
2026-03-17	GERN	-0.03	-4.13	9.97
2026-03-18	GERN	-0.03	-4.13	9.97
2026-03-19	GERN	-0.03	-4.13	9.97
2026-03-20	GERN	-0.03	-4.13	9.97
2026-03-23	GERN	-0.03	-4.13	9.97
2026-03-24	GERN	-0.03	-4.13	9.97
2026-03-25	GERN	-0.03	-4.13	10.40
2026-03-26	GERN	-0.03	-4.13	10.40
2026-03-27	GERN	-0.03	-4.13	10.40
2026-03-30	GERN	-0.03	-4.13	10.40
2026-03-31	GERN	-0.03	-4.13	10.40
2026-04-01	GERN	-0.03	-4.13	10.40
2026-04-02	GERN	-0.03	-4.13	10.40
2026-04-06	GERN	-0.03	-4.13	10.40
2026-04-07	GERN	-0.03	-4.13	10.40
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.03

Avg. EPS Est. Current Quarter

-0.02

Avg. EPS Est. Next Quarter

-0.01

Insider Transactions

-0.03

Institutional Transactions

-4.13

Beta

0.73

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

67.3

Max Drawdown 5-Year %

-79

Target Price

3.4

P/E

Forward P/E

61.42

PEG

P/S

6.06

P/B

4.93

P/Free Cash Flow

EPS

-0.13

Average EPS Est. Cur. Y

-0.02

EPS Next Y. (Est.)

0.08

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-46.65

Relative Volume

0.97

Return on Equity vs Sector %

-64.4

Return on Equity vs Industry %

-47.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

◆ GERN Healthcare

$1.74

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

8/25

Volume

7/15

Valuation

12/20

TP/AR

1/10

Options

7/10

RSI

59.6

Range 1M

83.7%

Sup Dist

3.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

9/25

Growth

20/30

Estimates

2/20

Inst/Vol

5/15

Options

9/10

EPS Yr

66.7%

EPS NY

165.4%

52W%

74.7%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +70.8% upside

Quality

6/30

Valuation

16/30

Growth

15/25

Stability

4/10

LT Trend

3/5

Upside

+70.8%

Quality

Geron Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 258

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

GERN

Latest News

—

Caricamento notizie per GERN…

stock quote shares GERN – Geron Corporation Stock Price stock today

news today GERN – Geron Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch GERN – Geron Corporation yahoo finance google finance

stock history GERN – Geron Corporation invest stock market

stock prices GERN premarket after hours

ticker GERN fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GERN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y